Back to results
US 11,999,751 B2Granted
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
AssigneesIncyte Corporation, Incyte Holdings Corporation
InventorsYun-Long Li, Andrew P. Combs
Life of this patent
Estimating the term…
Abstract
This application relates to derivatives of Formula I: and pharmaceutically acceptable salts thereof, which are inhibitors of PI3K, and compositions and methods of treatment related thereto.
Claims12
A pharmaceutical composition comprising a compound selected from:
- 4-{3-chloro-6-ethoxy-2-fluoro-5-[1-([1,3]thiazolo[5,4-d]pyrimidin-7-ylamino)ethyl]phenyl}pyrrolidin-2-one;
- 4-{3-chloro-6-ethoxy-2-fluoro-5-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}pyrrolidin-2-one;
- 5-{3-chloro-6-methoxy-2-methyl-5-[(1S)-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}-N,N-dimethylpyridine-2-carboxamide;
- and
- 4-chloro-N-ethyl-3′,5′-difluoro-3-methyl-6-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]biphenyl-2-carboxamide;
- or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
3 more elements
A compound, which is 4-{3-chloro-6-ethoxy-2-fluoro-5-[1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl]phenyl}pyrrolidin-2-one, or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.